MedTrace Logo

Intraocular Bevacizumab (Avastin) for Rubeosis Iridis

NCT00557232 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2011-11-29

No results posted yet for this study

Summary

Bevacizumab (Avastin®, Roche, Rio de Janeiro, Brazil) is an anti-VEGF recombinant humanized monoclonal IgG1 antibody used to treat colorectal cancers. Bevacizumab may have a role in treating ocular disorders involving fibrovascular proliferation. To determine whether intraocular bevacizumab decreases rubeosis iridis in patients with neovascular glaucoma.

Conditions

Interventions

DRUG

bevacizumab

1.25mg/month

Sponsors & Collaborators

  • Instituto de Olhos de Goiania

    lead OTHER

Principal Investigators

  • Joao J Nassaralla, Jr. · Instituto de Olhos de Goiânia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2011-10-31
Completion
2011-11-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00557232 on ClinicalTrials.gov